These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19099214)

  • 1. [Antibody therapy in hematology and oncology - part 1].
    Kneba M; Schrader C; Köhne H
    Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
    Ogura M
    Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
    Skrabs C; Müller C; Agis H; Mannhalter C; Jäger U
    Leukemia; 2002 Sep; 16(9):1884-6. PubMed ID: 12200717
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monoclonal antibody treatment of malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Internist (Berl); 2004 Dec; 45(12):1370-7. PubMed ID: 15517123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.
    Seymour JF
    Nat Rev Clin Oncol; 2009 Nov; 6(11):624-6. PubMed ID: 19861993
    [No Abstract]   [Full Text] [Related]  

  • 6. [New antibodies in cancer treatment].
    Pestalozzi BC; Knuth A
    Praxis (Bern 1994); 2004 Sep; 93(39):1589-92. PubMed ID: 15500243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematology: The case against rituximab maintenance.
    Cheson BD
    Nat Rev Clin Oncol; 2009 Nov; 6(11):622-4. PubMed ID: 19861992
    [No Abstract]   [Full Text] [Related]  

  • 9. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
    Korolenko VO; Gershanovich ML; Tikhonova VV
    Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
    D'Antonio A; Boscaino A; Addesso M; Liguori G; Nappi O
    South Med J; 2008 Nov; 101(11):1168-9. PubMed ID: 19088534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of follicular lymphoma of the duodenum treated with the combined therapy of anti-CD20 antibody and chemotherapy].
    Isogai K; Yamamoto E; Yamaoka S; Tarasawa I; Murakami R; Morimoto I; Obata T; Mori M; Endo T; Imai K
    Nihon Shokakibyo Gakkai Zasshi; 2006 Mar; 103(3):301-9. PubMed ID: 16688961
    [No Abstract]   [Full Text] [Related]  

  • 15. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by
    Smith MR; Hong F; Li H; Gordon LI; Gascoyne RD; Paietta EM; Advani RH; Forero-Torres A; Horning SJ; Kahl BS
    Leukemia; 2017 Feb; 31(2):517-519. PubMed ID: 27780968
    [No Abstract]   [Full Text] [Related]  

  • 16. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
    Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on lymphomas.
    Staudt LM; Wilson WH
    Cancer Cell; 2002 Nov; 2(5):363-6. PubMed ID: 12450791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.